We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

111 hedge funds and large institutions have $561M invested in CytomX Therapeutics in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 40 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

8,350% more call options, than puts

Call options by funds: $169K | Put options by funds: $2K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.14% less ownership

Funds ownership: 84.06% → 83.92% (-0.14%)

8% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 40

9% less funds holding

Funds holding: 122 → 111 (-11)

20% less capital invested

Capital invested by funds: $698M → $561M (-$137M)

38% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 26

Holders
111
Holders Change
-11
Holders Change %
-9.02%
% of All Funds
2.47%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
37
Reduced
40
Closed
26
Calls
$169K
Puts
$2K
Net Calls
+$167K
Net Calls Change
+$1.07M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$31.9M
2
RI
RTW Investments
New York
+$13.5M
3
CAM
Cormorant Asset Management
Massachusetts
+$4.4M
4
PA
Perceptive Advisors
New York
+$3.71M
5
AG
Artal Group
Luxembourg
+$2.23M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$15.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.2M
3
State Street
State Street
Massachusetts
-$6.55M
4
Franklin Resources
Franklin Resources
California
-$6.17M
5
CC
Casdin Capital
New York
-$3.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$2.81M -$420K -28,325 -13%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$2.8M +$163K +11,007 +6%
TCIM
28
TIAA CREF Investment Management
New York
$2.5M -$35.2K -2,374 -1%
GIM
29
Granahan Investment Management
Massachusetts
$2.47M -$52.5K -3,541 -2%
PAG
30
Private Advisor Group
New Jersey
$2.46M +$1.23K +83 +0.1%
Millennium Management
31
Millennium Management
New York
$2.39M -$876K -59,053 -27%
AG
32
Artal Group
Luxembourg
$2.27M +$2.23M +150,000 New
JP Morgan Chase
33
JP Morgan Chase
New York
$2.16M -$111K -7,514 -5%
Man Group
34
Man Group
United Kingdom
$2.07M -$577K -38,899 -22%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$2.02M +$169K +11,365 +9%
USAA
36
United Services Automobile Association
Texas
$1.98M +$1.08M +72,872 +126%
Citigroup
37
Citigroup
New York
$1.97M +$1.44M +97,215 +292%
MCM
38
Moore Capital Management
New York
$1.89M – – –
CPC
39
Congress Park Capital
New York
$1.86M +$165K +11,125 +10%
Wells Fargo
40
Wells Fargo
California
$1.63M +$196K +13,240 +14%
VIA
41
Vident Investment Advisory
Georgia
$1.61M +$194K +13,058 +14%
AllianceBernstein
42
AllianceBernstein
Tennessee
$1.48M – – –
PAM
43
Panagora Asset Management
Massachusetts
$1.34M -$1.36M -91,709 -51%
UBS Group
44
UBS Group
Switzerland
$1.31M +$1.12M +75,258 +635%
Morgan Stanley
45
Morgan Stanley
New York
$1.27M -$174K -11,703 -12%
Squarepoint
46
Squarepoint
New York
$1.21M -$147K -9,879 -11%
HP
47
Harbourvest Partners
Massachusetts
$1.2M – – –
AG
48
Algert Global
California
$1.14M +$130K +8,777 +13%
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.14M +$40.1K +2,700 +4%
Invesco
50
Invesco
Georgia
$1.09M -$233K -15,677 -18%
1
2
3 4 5

CTMX Hedge Fund Activity: Q4 2018 in Review

111 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2018, worth a combined $561M — down 20% from $698M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of CTMX and 16 opened new positions — a net loss of 10 holders — while 40 trimmed existing stakes and 37 added.

The largest buyer was Wellington Management Group, adding an estimated $31.9M. The largest seller was Vanguard Group, cutting an estimated $15.6M.

  • 111 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2018, down from 122 in Q3 2018.
  • Funds reported $561M of CytomX Therapeutics stock for Q4 2018, down 20% quarter-over-quarter.
  • 16 funds opened new CytomX Therapeutics positions in Q4 2018 and 26 closed out, a net change of -10 holders.
  • The largest CytomX Therapeutics buyer in Q4 2018 was Wellington Management Group, an estimated $31.9M added.
  • The largest CytomX Therapeutics seller in Q4 2018 was Vanguard Group, an estimated $15.6M sold.

Based on aggregated 13F filings for Q4 2018.